ABOUT US
FOR UM INVESTIGATORS
TECHNOLOGIES
LABORATORIES AND SERVICES
EDUCATION
CONTACT US
NEWS
Miller School of Medicine >> UM Innovation >> Coulter Center
 
ID# CC001
More Details
Contact
Technology Breakthrough Treatment for Asthma and Other Inflammatory Lung Diseases
Scientific Revelance The main pathological feature of asthma is airway inflammation. Researchers at the University of Miami have identified the molecule that is responsible for triggering a chain of events that induce asthma. Studies in a mouse asthma model have demonstrated that blockage of this pathway prevents lung inflammation.
Commercial Opportunity Estimated at $14 billion in direct medical expenditures, treatment of asthma remains an important public health problem associated with significant health care costs.
Competitve Advantage
  • Target specificity unparalleled in conventional treatments
  • Reduce or eliminate many of the side-effects of current treatments
  • Could cure asthma and other inflammatory lung diseases
Inventors Drs. Eckhard Podack, Vadim Deyev, and Robert Levy
ID# CC002
More Details
Contact
Technology Novel Device for Cell Therapy
Scientific Revelance Transplantation of pancreatic Langerhans islets into subcutaneous, neovascularized devices is one of the possibilities currently explored as part of a search for a cure of diabetes as such transplantations could normalize metabolic control in a way that has been virtually impossible to achieve with exogenous insulin. Syngeneic islets transplanted into a subcutaneous, neovascularized device have been recently shown to restore euglycemia and sustain function long-term in a rat model.
Commercial Opportunity Diabetes is an increasing worldwide problem, and the need for diabetes-focused drug discovery is well underlined by the fact that whereas mortality rates for heart attacks, breast cancer, and stroke have significantly improved in the US since the 1980s due to the introduction of new drugs and therapeutic methods, they increased for diabetes. The incidence of Type 1 Diabetes has also increased while the age of onset has decreased by 3–5 years over the past decade for yet unknown reasons.
Competitve Advantage The novel approach requires much smaller doses than a traditional systemic immunosuppression since therapeutically active concentration levels have to be maintained only within the device (by local delivery). Therefore, the serious toxic side effects and the susceptibility for opportunistic infections, the main problems associated with systemic therapies, should be avoidable even if long-time treatment is needed to provide protection against rejection and maintain function.
Inventors Dr. Camillo Ricordi
ID# CC003
More Details
Contact
Technology Novel Small Molecules for Promoting Nerve Regeneration
Scientific Revelance

Unlike most other tissues which have the ability to heal themselves after injury, damaged axons in the central nerve system are unable to regenerate. There are no existing therapies to promote CNS axon regeneration in humans. Identification of novel small molecules that promote nerve growth and nerve regeneration could provide compounds that can be manipulated to yield drugs useful in treatment of various neurodegenerative diseases.
Commercial Opportunity Health care costs for CNS patients are staggering. For instance, the patient costs are estimated at $13 billion annually for SCI patients in the U.S alone. Concerns about the specificity and efficacy of agents reported in the literature, researchers at the University of Miami and New York University have synthesized a novel family of small molecules that are potent and selective in promoting axon regeneration.
Competitve Advantage
  • Potent and Selective
  • Novel mechanisms that could lead to new therapy strategies
Inventors Drs. John Bixby, Vance Lemmon, Lynn Usher (UM), Young-Tae Chang, Jae-Wook Lee, and Jaeki Min (NYU).
ID# CC004
More Details
Contact
Technology A Novel Cell/Tissue Culture System to Enhance Cell Proliferation & Induce Cell Differentiation
Scientific Revelance Conventional cell and tissue culture typically involved cells resting atop (or attaching to) a gas-impermeable plastic bottom, in a given volume of specific medium to maintain viability and function. For immortalized cell lines or cells that are not exquisitely depend on oxygen, this means of culture is sufficient and results in acceptable growth and differentiation for experimental needs. However, these conditions are sub-optimal for tissues with high metabolic requirements. The researchers at the University of Miami have designed a novel culture system whereby three dimensional tissues can receive oxygen both from the top (after diffusion through medium) and the bottom (through direct diffusion across a perfluorohydrocarbon-silicon membrane).
Commercial Opportunity The Petri dish market is over two billion dollars a year. This novel system can be used to promote both growth and differentiation of stem/progenitor cells where oxygen becomes limiting as is invariably the case in conventional culture systems. Such application is of particular interest for cell types known for their high in vivo oxygen demands. The premise behind this approach is that, unless culture systems meet the physiological requirements of such cells, their in vitro differentiation from stem cells will be severely impaired. Among the tissues with a high metabolic rate whose differentiation may benefit from our invention are: pancreatic islet cells, liver, kidney, cardiac tissue, brain cells and lung epithelium, to name a few. Additionally, this device could also be used to improve the culture of primary or already differentiated tissues.
Competitve Advantage
  • Provides a more physiological mode of oxygen delivery, preventing hypoxia even in thick cellular aggregates.
  • Promotes cell viability and function
  • Enhances differentiation in stem cell systems where oxygen has been proven to act directly as a cell specification agent.
Inventors Drs. Christopher A. Fraker, Juan Dominguez-Bendala, Camillo Ricordi & Luca Inverardi.
ID# CC005
More Details
Contact
Technology Rapid Identification of Ocular Fungal and Amoebic Pathogens
Scientific Revelance Fungal infection of the eye, or ocular mycosis, is a serious condition that may result in loss of vision if the disease is not diagnosed and treated in time. Despite an increase in the incidence of the disease over the last decades, management remains a clinical challenge due to misdiagnosis and inadequate detection methods, which are often slow.
Commercial Opportunity Mycotic keratitis is considered a leading cause of ocular morbidity throughout the world. This corneal infection, which is mostly caused by yeast or filamentous fungi, can have devastating and irreversible effects if not treated on time. For instance, if the disease is left untreated, 50% of infected eyes can suffer from visual impairment or loss of sight due to irreversible corneal damage. The incidence of the disease, which has increased over the past four decades, has been the result of overuse of topical steroids and antibacterial agents, the rise in the number of patients with immuno-deficiencies, trauma, chronic ocular diseases and corneal anesthetic abuse. Contact lens wearers are also a growing sector of the population at risk for fungal keratitis.
Competitve Advantage
  • High speed and high sensitivity for rapid and accurate diagnosis
  • Inexpensive
  • Versatile as a variety of probes can be added or subtracted to create different arrays that can be employed in a wide variety of applications
Inventors Drs. Eduardo C. Alfonso and Jack W. Fell
UMF-101
More Details
Contact
Technology Immunomodulating Tumor Necrosis Factor Receptor 25 (TNFR25) Agonists, Antagonists and Immunotoxins
Scientific Revelance The invention uses immunomodulating agents that can both stimulate the immune system or have an immunosuppressive effect. TNFR25 agonists and antagonists have pro and anti-inflammatory action, respectively. TNFR25 agonists can support tumor vaccination, while TNFR25 antagonists can treat disease caused by chronic inflammation and autoimmunity (e.g. inflammatory bowel disease, ulcerative colitis and Crohn's Disease).
Commercial Opportunity Inflammatory bowel disease, ulcerative colitis and Crohn's disease cost between $3-5 billion annually to treat. To have a novel approach to these diseases that would also apply to transplantation autoimmunity is a unique commercial opportunity.
Competitve Advantage

Tumor vaccines that are currently available are often suppressed in the tumor environment. This approach increases the vaccine's ability to act on the tumor due to increased stability. The myriad of biological effects that this immunomodulating agent can achieve is far superior to anything currently in use.
Inventors Vadim Deyev, Robert B. Levy and Eckhard R. Podack
UMG-145
More Details
Contact
Technology A Transcriptomic Biomarker of Myocarditis
Scientific Revelance Myocarditis is a common inflammatory disease of the heart, estimated to account for about 30% of heart failure. Conventional diagnostic methods include 4-6 endomyocardial biopsies with consequent histologic evaluation. However, this standard technique results in a false negative rate of about 55%. The currently developed biomarker enables prediction of the likelihood of having inflammatory heart disease from a single endomyocardial biopsy with a sensitivity that greatly exceeds current standards. Furthermore, there is evidence that the biomarker may be detected in blood cells. Therefore, a simple venipuncture to detect the developed biomarker may replace the need for a diagnostic biopsy.
Commercial Opportunity Myocarditis is an inflammatory disease of the heart, accounting for about 30% of heart failure. Given that specific treatment for myocarditis can reverse the disease process, the need for accurate identification of patients becomes apparent.
Competitve Advantage

There is no simple way to predict myocarditis especially in asymptomatic patients. Having access to a unique molecular signature associated with various aspects of cardiac diseases and disorders may allow for identification of patients with myocarditis with a positive predictive value of 80%. This would allow for patient treatment prior to symptoms and would add a huge number of potential patients to the market.
Inventors Joshua Hare and Bettina Heidecker
UMG-146
More Details
Contact
Technology A Transcriptomic Biomarker of Cardiac Diseases and Disorders
Scientific Revelance Although heart failure is a common disease with about 550,000 newly diagnosed patients every year, individual risk assessment is still an unsolved issue. Many prognostic factors have been suggested, but there is no agreement on a reliable standard. Furthermore, there is a need for improvements in the accuracy of diagnoses for heart disease. Conventional methods include endomyocardial biopsy and histologic evaluation of 4-6 samples. However, this standard technique results in a false negative rate of about 55%. Genetic biomarkers may allow us to predict the likelihood of having cardiac disease and related disorders and may be able to do so from a simple non-invasive blood test.
Commercial Opportunity Myocarditis is an inflammation of the myocardium, the thick muscular layer of the heart that accounts for about 30% of heart failure.
Competitve Advantage

There is no simple way to predict myocarditis especially in asymptomatic patients. Having access to a unique molecular signature associated with various aspects of cardiac diseases and disorders may allow us to have up to 80% positive predictive correlation. This would allow patient treatment prior to symptoms and add a huge number of potential patients to the market.
Inventors Joshua Hare and Bettina Heidecker
UMH-119
More Details
Contact
Technology Method for Treating Autoimmune Disorders
Scientific Revelance The invention is a method to identify and characterize CD4+ T cells that may be used in therapies for autoimmune diseases such as mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE).
Commercial Opportunity MCTD, SLE and rheumatoid arthritis are individually relatively rare conditions, but taken together, affect a substantial number of people. MCTD has an estimated prevalence of up to 15 cases per 100,000 people in the US. Lupus and rheumatoid arthritis are estimated to affect 1.4 million and 2.5 million persons respectively, in the US. Currently, there are no cures for these conditions, and treatment is very limited, or do not exist.
Competitve Advantage

This technology presents an opportunity to expand market share by introducing a novel product that does not have much competition. At the present time, there are limited treatment options for autoimmune diseases such as MCTD and lupus.
Inventors Robert Hoffman
UMD-120
More Details
Contact
Technology Microparticles as a Treatment Method for Bleeding Disorders
Scientific Revelance Microparticles (MP) derived from blood can be administered to a patient to help stop bleeding and decrease blood clotting time. This would be important in cases involving internal bleeding, trauma, surgery, and chemotherapy, where the patient's own blood prior to treatment could be banked for later use.
Commercial Opportunity This technology addresses a critical necessity because of the endless need, and short supply, of blood and its products. The market for a platelet substitute product is significant. It is estimated that over 10,000,000 units of platelets were transfused in the United States last year at an average cost of $50 per unit, which equates to an a market potential of $500 million annually.
Competitve Advantage

At present, no synthetic microparticles or blood cells have emerged as being clinically useful. In addition, since the patient's own blood can be used, the risk of acquiring infectious agents from an external blood supply is decreased substantially.
Inventors Wenche Jy, Joaquin Jimenez, Lawrence Horstman, Yeon Ahn, and Eugene Ahn
 
UME-115
Contact
 
Technology Papillary Muscle Attachment Device for the Purpose of Left Ventricular Reduction in Patients with Dilated Cardiomyopathy
Scientific Revelance This invention encompasses novel minimally invasive methods and instruments to treat a common and deadly heart disease (Dilated Cardiomyopathy) that is currently difficult to treat and control. A small tether is implanted in the left ventricle chamber of the heart to prevent further abnormal expansion of the chamber.
Commercial Opportunity Cardiomyopathy is a growing public health problem. In the United States alone, 3 million people are currently living with cardiomyopathy, and another 400,000 are diagnosed each year.
Competitve Advantage

This less invasive surgery to treat cardiomyopathy reduces the use of drugs and the risk of heart failure. The competitive treatment drugs have side effects and do not alter the course of the disease. This procedure is much less invasive than a heart transplant.
Inventors Eduardo De Marchena

Copyright © 1997-2010
University of Miami,
All Rights Reserved.

 Terms of Use
Privacy Statement
Contact Us		 Medical Disclaimer
Site Map
Web Technology